PCA Investment Advisory Services’s Boston Scientific BSX Stock Holding History

PCA Investment Advisory Services’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-112	Closed	-$6.06K	–	150
2023 Q2	$6.06K	Buy	+112	New	+$5.85K	﹤0.01%	419

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCA Investment Advisory Services's BSX Position: Q3 2023 in Review

PCA Investment Advisory Services sold out of Boston Scientific (BSX) in Q3 2023, closing a stake of 112 shares — an estimated $6.06K sold.

PCA Investment Advisory Services first reported a position in BSX in Q2 2023 and held it in 1 quarter. The position peaked at $6.06K in Q2 2023. 1,056 funds tracked by Wall St. Rank hold BSX as of Q3 2023.

PCA Investment Advisory Services reported no remaining Boston Scientific position as of Q3 2023 after selling out during the quarter.
PCA Investment Advisory Services sold 112 Boston Scientific shares in Q3 2023, an estimated $6.06K.
PCA Investment Advisory Services first reported a position in Boston Scientific in Q2 2023 and held it in 1 quarter.
PCA Investment Advisory Services's Boston Scientific position peaked at $6.06K in Q2 2023.
1,056 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2023.

Based on PCA Investment Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.